Auris Medical AM-301 in encouraging preclinical action against SARS-CoV-2

 

• Auris Medical (EARS +63.1%) has announced efficacy data from testing AM-301 in vitro, a drug-free nasal spray for protection against airborne pathogens and allergens.
• AM-301 was tested for its capability to prevent or mitigate SARS-CoV-2 infection of nasal epithelial cells. In saline-treated control cultures, Sars-CoV-2 replicated efficiently, resulting in a rapid increase in viral titer. In contrast, daily treatment with AM-301, beginning right before inoculation, showed effective protection against viral infection.
• 48 hours post-infection, average virus titers were 90.0% lower than those observed in controls. 72 hours and 96 hours post-infection, average virus titers were 99.2 and 99.4% lower, respectively.
• The company says its looks forward to taking AM-301 through additional tests and advancing the program towards the submission of regulatory applications in 2021.
• https://seekingalpha.com/news/3640409-auris-medical-soars-afterminus-301-shows-encouraging-preclinical-action-against-sars-covminus